Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

吉西他滨 医学 危险系数 内科学 胰腺癌 脱氧胞苷 化疗 抗代谢物 胃肠病学 肿瘤科 临床研究阶段 癌症 置信区间
作者
Hideki Ueno,Tatsuya Ioka,Masafumi Ikeda,Shinichi Ohkawa,Hiroaki Yanagimoto,Narikazu Boku,Akira Fukutomi,Kazuya Sugimori,Hideo Baba,Kenji Yamao,Tomotaka Shimamura,Masayuki Sho,Masayuki Kitano,Ann‐Lii Cheng,Kazuhiro Mizumoto,Jen‐Shi Chen,Junji Furuse,Akihiro Funakoshi,Takashi Hatori,Taketo Yamaguchi
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:31 (13): 1640-1648 被引量:628
标识
DOI:10.1200/jco.2012.43.3680
摘要

PURPOSE: The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival. PATIENTS AND METHODS: The participants were chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m(2) on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m(2) on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle). RESULTS: In the total of 834 enrolled patients, median overall survival was 8.8 months in the gemcitabine group, 9.7 months in the S-1 group, and 10.1 months in the gemcitabine plus S-1 group. The noninferiority of S-1 to gemcitabine was demonstrated (hazard ratio, 0.96; 97.5% CI, 0.78 to 1.18; P < .001 for noninferiority), whereas the superiority of gemcitabine plus S-1 was not (hazard ratio, 0.88; 97.5% CI, 0.71 to 1.08; P = .15). All treatments were generally well tolerated, although hematologic and GI toxicities were more severe in the gemcitabine plus S-1 group than in the gemcitabine group. CONCLUSION: Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
奋斗蛋挞发布了新的文献求助30
1秒前
1秒前
1秒前
1秒前
11发布了新的文献求助10
1秒前
2秒前
2秒前
刘艳娇完成签到 ,获得积分10
3秒前
周一发布了新的文献求助10
4秒前
赘婿的应助被HXuer采纳,获得10
4秒前
炒栗子发布了新的文献求助10
4秒前
经十路以东的应助被杨茜然采纳,获得30
5秒前
shark发布了新的文献求助10
5秒前
饱满鞅发布了新的文献求助10
6秒前
czcz完成签到,获得积分10
6秒前
6秒前
7秒前
7秒前
8秒前
JamesPei的应助被王博涵采纳,获得10
8秒前
领导范儿的应助被San采纳,获得10
9秒前
兜兜发布了新的文献求助20
9秒前
冷静白山完成签到,获得积分10
9秒前
Ava的应助被侃侃采纳,获得10
9秒前
123发布了新的文献求助10
10秒前
11秒前
11秒前
12秒前
12秒前
利多卡因完成签到,获得积分10
12秒前
12秒前
13秒前
852的应助被你好采纳,获得10
13秒前
13秒前
14秒前
桥波发布了新的文献求助10
14秒前
NexusExplorer的应助被Waitcy采纳,获得10
14秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193925
求助须知:如何正确求助?哪些是违规求助? 9579945
关于积分的说明 21868504
捐赠科研通 7793568
什么是DOI,文献DOI怎么找? 3437462
关于科研通互助平台的介绍 2560923
邀请新用户注册赠送积分活动 2484250